{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:15:14Z","timestamp":1722885314931},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1245\/s10434-024-14963-0","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T14:02:30Z","timestamp":1706536950000},"page":"3513-3522","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting Recurrence After Radical Surgery for High-Risk Renal Cell Carcinoma: Development and Internal Validation of the \u201cTOWARDS\u201d Score"],"prefix":"10.1245","volume":"31","author":[{"given":"Yudai","family":"Ishiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Omae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"14963_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2021.04.042","volume":"80","author":"J Bedke","year":"2021","unstructured":"Bedke J, Albiges L, Capitanio U, et al. The 2021 Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-na\u00efve metastatic clear-cell renal cell carcinoma are standard of care. Eur Urol. 2021;80:393\u20137.","journal-title":"Eur Urol."},{"key":"14963_CR2","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.2006.06.1218","volume":"25","author":"PI Karakiewicz","year":"2007","unstructured":"Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25:1316\u201322.","journal-title":"J Clin Oncol."},{"key":"14963_CR3","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/cncr.11234","volume":"97","author":"BC Leibovich","year":"2003","unstructured":"Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663\u201371.","journal-title":"Cancer."},{"key":"14963_CR4","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1016\/j.clgc.2020.12.005","volume":"19","author":"L Marconi","year":"2021","unstructured":"Marconi L, Sun M, Beisland C, et al. Prevalence, disease-free, and overall survival of contemporary patients with renal cell carcinoma eligible for adjuvant checkpoint inhibitor trials. Clin Genitourin Cancer. 2021;19:e92\u20139.","journal-title":"Clin Genitourin Cancer."},{"key":"14963_CR5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","volume":"23","author":"T Powles","year":"2022","unstructured":"Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:1133\u201344.","journal-title":"Lancet Oncol."},{"key":"14963_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.juro.2017.04.066","volume":"198","author":"EJ Abel","year":"2017","unstructured":"Abel EJ, Masterson TA, Karam JA, et al. Predictive nomogram for recurrence following surgery for nonmetastatic renal cell cancer with tumor thrombus. J Urol. 2017;198:810\u20136.","journal-title":"J Urol."},{"key":"14963_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0022-5347(05)66077-6","volume":"166","author":"MW Kattan","year":"2001","unstructured":"Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63\u20137.","journal-title":"J Urol."},{"key":"14963_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.eururo.2021.02.025","volume":"80","author":"AF Correa","year":"2021","unstructured":"Correa AF, Jegede OA, Haas NB, et al. Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma. Eur Urol. 2021;80:20\u201331.","journal-title":"Eur Urol."},{"key":"14963_CR9","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1200\/JCO.2001.19.6.1649","volume":"19","author":"A Zisman","year":"2001","unstructured":"Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649\u201357.","journal-title":"J Clin Oncol."},{"key":"14963_CR10","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1093\/annonc\/mdx492","volume":"28","author":"S Buti","year":"2017","unstructured":"Buti S, Puligandla M, Bersanelli M, et al. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol. 2017;28:2747\u201353.","journal-title":"Ann Oncol."},{"key":"14963_CR11","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KG Moons","year":"2015","unstructured":"Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1-73.","journal-title":"Ann Intern Med."},{"key":"14963_CR12","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Wiley, Hoboken, NJ; 2017."},{"key":"14963_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","volume":"6","author":"SA Fuhrman","year":"1982","unstructured":"Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655\u201363.","journal-title":"Am J Surg Pathol."},{"key":"14963_CR14","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","volume":"37","author":"B Delahunt","year":"2013","unstructured":"Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490\u2013504.","journal-title":"Am J Surg Pathol."},{"key":"14963_CR15","unstructured":"Gregg J, Scarpato K. Surgical approaches for open renal surgery, including open radical nephrectomy. In: Hinman\u2019s Atlas of urologic surgery. 4th ed. Elsevier, Philadelphia, PA, 2018."},{"key":"14963_CR16","unstructured":"Orden M, Landman J. Laparoscopic nephrectomy. In: Hinman\u2019s Atlas of urologic surgery. 4 ed. Elsevier, Philadelphia, PA, 2018."},{"key":"14963_CR17","doi-asserted-by":"publisher","first-page":"l737","DOI":"10.1136\/bmj.l737","volume":"365","author":"LJ Bonnett","year":"2019","unstructured":"Bonnett LJ, Snell KIE, Collins GS, Riley RD. Guide to presenting clinical prediction models for use in clinical settings. BMJ. 2019;365:l737.","journal-title":"BMJ."},{"key":"14963_CR18","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/sim.1742","volume":"23","author":"LM Sullivan","year":"2004","unstructured":"Sullivan LM, Massaro JM, D\u2019Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med. 2004;23:1631\u201360.","journal-title":"Stat Med."},{"issue":"167","key":"14963_CR19","first-page":"e161","volume":"40","author":"C Palumbo","year":"2022","unstructured":"Palumbo C, Perri D, Zacchero M, et al. Risk of recurrence after nephrectomy: comparison of predictive ability of validated risk models. Urol Oncol. 2022;40(167):e161\u20137.","journal-title":"Urol Oncol."},{"key":"14963_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.eururo.2018.01.005","volume":"73","author":"BC Leibovich","year":"2018","unstructured":"Leibovich BC, Lohse CM, Cheville JC, et al. Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol. 2018;73:772\u201380.","journal-title":"Eur Urol."},{"key":"14963_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2022.09.026","volume":"83","author":"U Capitanio","year":"2023","unstructured":"Capitanio U, Bedke J, Albiges L, et al. A renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2023;83:3\u20135.","journal-title":"Eur Urol."},{"key":"14963_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.eururo.2007.01.106","volume":"52","author":"JS Lam","year":"2007","unstructured":"Lam JS, Klatte T, Patard JJ, et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol. 2007;52:155\u201362.","journal-title":"Eur Urol."},{"key":"14963_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.eururo.2010.07.006","volume":"58","author":"G Novara","year":"2010","unstructured":"Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol. 2010;58:588\u201395.","journal-title":"Eur Urol."},{"key":"14963_CR24","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","volume":"387","author":"NB Haas","year":"2016","unstructured":"Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008\u201316.","journal-title":"Lancet."},{"key":"14963_CR25","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00345-018-2309-4","volume":"36","author":"T Klatte","year":"2018","unstructured":"Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018;36:1943\u201352.","journal-title":"World J Urol."},{"issue":"3","key":"14963_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/OP.21.00419","volume":"18","author":"J Tran","year":"2022","unstructured":"Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract. 2022;18(3):187\u201396.","journal-title":"JCO Oncol Pract."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-14963-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-14963-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-14963-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T16:05:29Z","timestamp":1712333129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-14963-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["14963"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-14963-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kenji Omae received honoraria from Pfizer and Ono Pharmaceutical. Tsunenori Kondo received honoraria from Pfizer, Takeda, MSD, and Ono Pharmaceutical. Toshio Takagi received honoraria from Ono Pharmaceutical. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}